Workflow
乙酰唑胺片
icon
Search documents
灵康药业:乙酰唑胺缓释胶囊获药物临床试验批准
news flash· 2025-04-28 08:07
Group 1 - The company Lingkang Pharmaceutical (603669) announced that its wholly-owned subsidiary, Hainan Lingkang Pharmaceutical Co., Ltd., has received the Clinical Trial Approval Notice for Acetazolamide Sustained-Release Capsules from the National Medical Products Administration [1] - The drug is intended for the prevention or improvement of acute mountain sickness symptoms that may occur under gradually increasing conditions [1] - As of the announcement date, the company has invested 6.9 million RMB in research and development expenses [1] Group 2 - According to IMS data, the sales revenue of Acetazolamide tablets in China is projected to be 4.4352 million RMB in the first half of 2024 [1]